Prnewswireยท2025-09-20 12:00Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, briquilimab [1][2]. Group 1: Allegations - The lawsuit claims that Jasper Therapeutics failed to disclose critical information about its manufacturing controls and procedures, which were necessary to ensure compliance with cGMP regulations [2]. - The lack of proper controls increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, including briquilimab [2]. - This situation heightened the likelihood of disruptive cost-reduction measures, leading to an overstatement of the company's business and financial prospects [2]. Group 2: Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decline, closing at $3.04 per share [3]. Group 3: Class Action Participation - Shareholders who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible to participate in the class action [1][4]. - Interested shareholders can contact Robbins LLP to serve as lead plaintiff or remain as absent class members without participating in the case [4].